论文部分内容阅读
目的探讨CUEDC2在乳腺浸润性癌组织中的表达特点及与临床病理特征、雌激素受体(ER)、孕激素受体(PR)、增殖抗原(Ki-67)和人表皮生长因子受体2(Her-2)基因扩增情况的关系。方法采用免疫组化检测163例乳腺不同病变组织中CUEDC2、ER、PR、Ki-67和Her-2的表达水平,FISH技术检测Her-2基因扩增情况,结合患者相关资料进行分析。结果 CUEDC2在乳腺浸润性导管癌、乳腺导管内癌的阳性率分别为72.8%、63.3%,明显高于正常乳腺组织的10%,差异显著(P<0.05)。CUEDC2表达水平与浸润性导管癌患者的淋巴结转移、组织学分级有明显相关性(P<0.05),与年龄、肿瘤大小、临床分期无关(P>0.05)。在浸润性导管癌不同分子亚型中,luminal A型CUEDC2表达率最低,三阴型最高(P<0.05)。CUEDC2表达水平与ER(r=-0.703,P<0.05)、PR(r=-0.798,P<0.05)表达程度呈负相关;与Ki-67(r=0.414,P<0.05)表达、Her-2基因扩增(r=0.359,P<0.05)表达程度呈正相关。结论 CUEDC2表达与乳腺癌的发生、发展、转移及分子分型有关,其高表达是预后不良的预测因子。
Objective To investigate the expression of CUEDC2 in breast invasive carcinoma and its relationship with clinicopathological characteristics, estrogen receptor (ER), progesterone receptor (PR), proliferating antigen (Ki-67) and human epidermal growth factor receptor 2 (Her-2) gene amplification relationship. Methods Immunohistochemistry was used to detect the expression of CUEDC2, ER, PR, Ki-67 and Her-2 in 163 cases of breast lesions. The amplification of Her-2 gene was detected by FISH and the related data were analyzed. Results The positive rates of CUEDC2 in invasive ductal carcinoma and intraductal carcinoma were 72.8% and 63.3%, respectively, which were significantly higher than those in normal breast tissue (P <0.05). The expression of CUEDC2 was significantly correlated with lymph node metastasis and histological grade in invasive ductal carcinoma (P <0.05), but not with age, tumor size and clinical stage (P> 0.05). Among the different molecular subtypes of invasive ductal carcinoma, luminal A type CUEDC2 had the lowest expression rate and the highest triple-negative type (P <0.05). The expression of CUEDC2 was negatively correlated with the expression of ER (r = -0.703, P <0.05), PR (r = -0.798, P <0.05) 2 gene amplification (r = 0.359, P <0.05) showed a positive correlation. Conclusion The expression of CUEDC2 is related to the occurrence, development, metastasis and molecular typing of breast cancer. The high expression of CUEDC2 is a predictor of poor prognosis.